SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

A closed sign hanging on the door of a business
Manufacturing
Vitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concerns
Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to possible superpotency that could cause a range of adverse events.
August 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Manufacturing
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
August 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3d rendering of Radiopharmaceuticals, these are radioactive medications or radioisotopes. These medications can be delivered orally in pill form.
Manufacturing
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.
August 25, 2026
 · 
4 min read
 · 
Nick Paul Taylor
GLP-1 weighloss pills - five pills in a row on blue background with harsh lighting - orthographic perspective
Weight loss
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
August 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Rare disease ribbon with cut-outs of people
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Checklist, Icon, Clipboard, List, Questionnaire
Gene therapy
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
Cancer
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
August 19, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Obesity
Enveda’s exercise-simulating obesity tablet clears early clinical test
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
August 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Sleeping girl in the pill bottles. concept of pills, good sleep, Insomnia, exhausted and frustrated
Neuroscience
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
August 19, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Business negotiation, deal making or acquisition, merger vector concept. Two men shaking hands. Minimal design. Eps10 illustration
Manufacturing
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
August 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Neon arrow sign showing a jumbo reversal of fortune
Manufacturing
Rebounding biotech funds expected to spur CDMO growth within year
With demand for pharma services historically lagging behind changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.
August 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
world map with red and orange colors over a dark color illustrations background
Manufacturing
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.
August 14, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Email envelope with warning sign on white background
Manufacturing
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
August 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
High angle night view of the city skyline at Huaian Bridge in Shijiazhuang, Hebei Province, China
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
August 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A crushing blow to business and economic growth. Stopping income rise and welfare growth. Mitigate dangers and reduce risks. Anticipate the main blow of the crisis. End of career. Bankruptcy.
Earnings
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.
August 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor